AAPL334.51+2.24 (+0.67%) ▲|ABBV261.43+4.31 (+1.68%) ▲|ABT102.95+1.00 (+0.98%) ▲|ACN194.28+10.38 (+5.64%) ▲|ADBE264.86+12.63 (+5.01%) ▲|AMAT426.96-29.53 (-6.47%) ▼|AMD494.09-22.05 (-4.27%) ▼|AMGN380.37+3.02 (+0.80%) ▲|AMT177.20-0.65 (-0.37%) ▼|AMZN255.59-1.19 (-0.46%) ▼|AVGO346.64-15.36 (-4.24%) ▼|AXP326.91+2.22 (+0.68%) ▲|BA210.37-0.09 (-0.04%) ▼|BAC60.11-2.59 (-4.12%) ▼|BKNG175.20+1.28 (+0.74%) ▲|BLK1,066.89-12.76 (-1.18%) ▼|BMY64.12+0.48 (+0.75%) ▲|BNY158.30-4.36 (-2.68%) ▼|BRK-B513.81+3.44 (+0.67%) ▲|C133.83-4.99 (-3.59%) ▼|CAT786.08-32.50 (-3.97%) ▼|CL88.34+1.54 (+1.77%) ▲|CMCSA24.98-0.22 (-0.87%) ▼|COF207.37-0.94 (-0.45%) ▼|COP137.69+0.34 (+0.25%) ▲|COST917.05+12.28 (+1.36%) ▲|CRM258.90+11.18 (+4.51%) ▲|CSCO111.49-0.65 (-0.58%) ▼|CVS95.67+1.01 (+1.07%) ▲|CVX213.68-0.39 (-0.18%) ▼|DE681.39+5.65 (+0.84%) ▲|DHR203.41+3.27 (+1.63%) ▲|DIS109.18+2.63 (+2.47%) ▲|DUK118.88-0.54 (-0.45%) ▼|EMR148.37-3.82 (-2.51%) ▼|FDX311.61+0.84 (+0.27%) ▲|GD356.78+0.88 (+0.25%) ▲|GE317.29-6.38 (-1.97%) ▼|GEV873.25-84.02 (-8.78%) ▼|GILD145.74+2.02 (+1.41%) ▲|GM86.41+0.79 (+0.92%) ▲|GOOG345.45+10.00 (+2.98%) ▲|GOOGL348.92+10.42 (+3.08%) ▲|GS990.42-38.76 (-3.77%) ▼|HD310.54+1.80 (+0.58%) ▲|HON199.12-3.25 (-1.60%) ▼|IBM250.89+7.60 (+3.12%) ▲|INTC98.29-4.66 (-4.52%) ▼|INTU338.38+16.81 (+5.23%) ▲|ISRG376.21+7.06 (+1.91%) ▲|JNJ267.88+2.30 (+0.87%) ▲|JPM349.21-7.02 (-1.97%) ▼|KO89.14+0.85 (+0.96%) ▲|LIN464.53-1.70 (-0.36%) ▼|LLY1,145.82+30.12 (+2.70%) ▲|LMT527.84+3.65 (+0.70%) ▲|LOW198.37+1.55 (+0.79%) ▲|LRCX275.82-22.41 (-7.51%) ▼|MA575.04+5.85 (+1.03%) ▲|MCD257.19+4.66 (+1.85%) ▲|MDLZ62.38-0.06 (-0.10%) ▼|MDT93.31+2.35 (+2.58%) ▲|META664.45+16.42 (+2.53%) ▲|MMM162.01-2.96 (-1.79%) ▼|MO70.55+1.57 (+2.27%) ▲|MRK145.46+1.53 (+1.06%) ▲|MS207.18-7.21 (-3.36%) ▼|MSFT509.20+13.57 (+2.74%) ▲|MU926.10-49.17 (-5.04%) ▼|NEE82.21-0.10 (-0.12%) ▼|NFLX80.75+3.35 (+4.32%) ▲|NKE37.15+0.35 (+0.94%) ▲|NOW143.13+10.60 (+7.99%) ▲|NVDA212.42-5.88 (-2.69%) ▼|ORCL143.85-6.44 (-4.28%) ▼|PEP136.61+0.29 (+0.21%) ▲|PFE27.78+0.06 (+0.20%) ▲|PG146.24+0.97 (+0.67%) ▲|PLTR173.30+6.07 (+3.63%) ▲|PM193.93+2.87 (+1.50%) ▲|QCOM179.12-2.85 (-1.57%) ▼|RTX194.66-3.03 (-1.53%) ▼|SBUX98.86+0.12 (+0.12%) ▲|SCHW106.98-0.27 (-0.25%) ▼|SO86.85-0.33 (-0.37%) ▼|SPG204.76-0.08 (-0.04%) ▼|T26.44+0.38 (+1.46%) ▲|TMO612.15+2.33 (+0.38%) ▲|TMUS183.99+1.66 (+0.91%) ▲|TSLA362.69-2.75 (-0.75%) ▼|TXN264.64-4.06 (-1.51%) ▼|UBER72.76+1.09 (+1.52%) ▲|UNH384.33+7.56 (+2.01%) ▲|UNP284.54+0.14 (+0.05%) ▲|UPS101.69+1.41 (+1.41%) ▲|USB62.38-0.46 (-0.73%) ▼|V376.34+5.89 (+1.59%) ▲|VZ51.30+0.69 (+1.35%) ▲|WFC87.69-2.60 (-2.88%) ▼|WMT109.49+2.34 (+2.18%) ▲|XOM165.46-0.54 (-0.32%) ▼|AAPL334.51+2.24 (+0.67%) ▲|ABBV261.43+4.31 (+1.68%) ▲|ABT102.95+1.00 (+0.98%) ▲|ACN194.28+10.38 (+5.64%) ▲|ADBE264.86+12.63 (+5.01%) ▲|AMAT426.96-29.53 (-6.47%) ▼|AMD494.09-22.05 (-4.27%) ▼|AMGN380.37+3.02 (+0.80%) ▲|AMT177.20-0.65 (-0.37%) ▼|AMZN255.59-1.19 (-0.46%) ▼|AVGO346.64-15.36 (-4.24%) ▼|AXP326.91+2.22 (+0.68%) ▲|BA210.37-0.09 (-0.04%) ▼|BAC60.11-2.59 (-4.12%) ▼|BKNG175.20+1.28 (+0.74%) ▲|BLK1,066.89-12.76 (-1.18%) ▼|BMY64.12+0.48 (+0.75%) ▲|BNY158.30-4.36 (-2.68%) ▼|BRK-B513.81+3.44 (+0.67%) ▲|C133.83-4.99 (-3.59%) ▼|CAT786.08-32.50 (-3.97%) ▼|CL88.34+1.54 (+1.77%) ▲|CMCSA24.98-0.22 (-0.87%) ▼|COF207.37-0.94 (-0.45%) ▼|COP137.69+0.34 (+0.25%) ▲|COST917.05+12.28 (+1.36%) ▲|CRM258.90+11.18 (+4.51%) ▲|CSCO111.49-0.65 (-0.58%) ▼|CVS95.67+1.01 (+1.07%) ▲|CVX213.68-0.39 (-0.18%) ▼|DE681.39+5.65 (+0.84%) ▲|DHR203.41+3.27 (+1.63%) ▲|DIS109.18+2.63 (+2.47%) ▲|DUK118.88-0.54 (-0.45%) ▼|EMR148.37-3.82 (-2.51%) ▼|FDX311.61+0.84 (+0.27%) ▲|GD356.78+0.88 (+0.25%) ▲|GE317.29-6.38 (-1.97%) ▼|GEV873.25-84.02 (-8.78%) ▼|GILD145.74+2.02 (+1.41%) ▲|GM86.41+0.79 (+0.92%) ▲|GOOG345.45+10.00 (+2.98%) ▲|GOOGL348.92+10.42 (+3.08%) ▲|GS990.42-38.76 (-3.77%) ▼|HD310.54+1.80 (+0.58%) ▲|HON199.12-3.25 (-1.60%) ▼|IBM250.89+7.60 (+3.12%) ▲|INTC98.29-4.66 (-4.52%) ▼|INTU338.38+16.81 (+5.23%) ▲|ISRG376.21+7.06 (+1.91%) ▲|JNJ267.88+2.30 (+0.87%) ▲|JPM349.21-7.02 (-1.97%) ▼|KO89.14+0.85 (+0.96%) ▲|LIN464.53-1.70 (-0.36%) ▼|LLY1,145.82+30.12 (+2.70%) ▲|LMT527.84+3.65 (+0.70%) ▲|LOW198.37+1.55 (+0.79%) ▲|LRCX275.82-22.41 (-7.51%) ▼|MA575.04+5.85 (+1.03%) ▲|MCD257.19+4.66 (+1.85%) ▲|MDLZ62.38-0.06 (-0.10%) ▼|MDT93.31+2.35 (+2.58%) ▲|META664.45+16.42 (+2.53%) ▲|MMM162.01-2.96 (-1.79%) ▼|MO70.55+1.57 (+2.27%) ▲|MRK145.46+1.53 (+1.06%) ▲|MS207.18-7.21 (-3.36%) ▼|MSFT509.20+13.57 (+2.74%) ▲|MU926.10-49.17 (-5.04%) ▼|NEE82.21-0.10 (-0.12%) ▼|NFLX80.75+3.35 (+4.32%) ▲|NKE37.15+0.35 (+0.94%) ▲|NOW143.13+10.60 (+7.99%) ▲|NVDA212.42-5.88 (-2.69%) ▼|ORCL143.85-6.44 (-4.28%) ▼|PEP136.61+0.29 (+0.21%) ▲|PFE27.78+0.06 (+0.20%) ▲|PG146.24+0.97 (+0.67%) ▲|PLTR173.30+6.07 (+3.63%) ▲|PM193.93+2.87 (+1.50%) ▲|QCOM179.12-2.85 (-1.57%) ▼|RTX194.66-3.03 (-1.53%) ▼|SBUX98.86+0.12 (+0.12%) ▲|SCHW106.98-0.27 (-0.25%) ▼|SO86.85-0.33 (-0.37%) ▼|SPG204.76-0.08 (-0.04%) ▼|T26.44+0.38 (+1.46%) ▲|TMO612.15+2.33 (+0.38%) ▲|TMUS183.99+1.66 (+0.91%) ▲|TSLA362.69-2.75 (-0.75%) ▼|TXN264.64-4.06 (-1.51%) ▼|UBER72.76+1.09 (+1.52%) ▲|UNH384.33+7.56 (+2.01%) ▲|UNP284.54+0.14 (+0.05%) ▲|UPS101.69+1.41 (+1.41%) ▲|USB62.38-0.46 (-0.73%) ▼|V376.34+5.89 (+1.59%) ▲|VZ51.30+0.69 (+1.35%) ▲|WFC87.69-2.60 (-2.88%) ▼|WMT109.49+2.34 (+2.18%) ▲|XOM165.46-0.54 (-0.32%) ▼|
22.2 C
New York
Monday, September 14, 2026

Tag: technologies

newssourceFORcompanyinformationcontent1releasesmarket

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment

PARAMUS, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today Gabrail Cancer Center (GCC) in Canton, Ohio is now activated and open for enrolling patients in its Phase 2a clinical trial evaluating their continuous low-dose lenalidomide, STAR-LLD, for the treatment of multiple myeloma (MM). Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study’s lead investigator. Regional Medical Oncology Center, located in Wilson, NC, has also opened as the trial’s second active clinical site.

Semiconductor Devices for High-Temperature Applications: Revolutionizing Advanced Technology Markets

"In-Depth Analysis of the Market for Semiconductor Devices for High-Temperature Applications: Highlighting Segmentation by Material, Device Type, Operating Temperature, and Industry, Offering Insights into...

New England Biolabs® Announces Winners of the 2025 Monarch Nucleic Acid Purification Scholarship

Three recipients were recognized for research exemplifying the core tenets of Monarch – performance, sustainability and value. IPSWICH, Mass., June 12, 2025 /PRNewswire/ -- New...

Florida Poly co-hosts prominent international industrial engineering conference

LAKELAND, Fla., June 12, 2025 /PRNewswire/ -- Top industrial engineering and operations management professionals from more than 40 countries will gather in Central Florida...

Massive Space 4X Strategy Game, Galactic Civilizations IV Version 3.0 Now Available

A year's worth of feedback, suggestions and general improvements make their way into Stardock's massive update PLYMOUTH, Mich., June 12, 2025 /PRNewswire/ -- Stardock Entertainment has...

TMI Digital Launches Transcoastal Corp’s New Energy Investment-Focused Website

CHEYENNE, Wyo., June 12, 2025 (GLOBE NEWSWIRE) -- TMI Digital is pleased to announce the launch of the new website for Transcoastal Corp, specifically designed to inform and educate investors about the evolving landscape of energy investments. This strategic initiative aligns with TMI Digital's commitment to providing factual, informative resources to the investment community.

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement

SONA Unveils New Report on How Interior Designers Can Choose the Right Smart Blinds

SONA Launches Insightful Guide for Interior Designers 
SONA Launches Insightful Guide for Interior Designers

Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions

SINGAPORE, June 12, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement...

Aegon Annual General Meeting approves all resolutions

Amsterdam, June 12, 2025 - Aegon Ltd.'s Annual General Meeting of Shareholders (AGM) today approved all resolutions on the agenda. This included the final dividend for 2024 of EUR 0.19 per common share, bringing Aegon’s total dividend for 2024 to EUR 0.35 per common share. The meeting also approved all proposed appointments to the Board of Directors, including the reappointment of three existing members and the election of three new members.

VoIP-Pal Files Antitrust Lawsuit Against Google, Apple, and Samsung

VoIP-Pal files a new antitrust lawsuit against Apple, Google, and Samsung alleging antitrust violations.

Cyber Media Tour with AITO Concludes: Reaffirming Commitment to Global New Luxury Mobility

CHONGQING, China, June 12, 2025 /CNW/ -- From June 10 to 12,  AITO — a luxury brand in the world of high-end intelligent vehicles,...

Sandler Partners Welcomes Fred Silva as Director, Channel – Southwest

New Hire Announcement | Independent Technology Distributor Sandler Partners grows their team, adding Fred Silva as Director, Channel – Southwest. REDONDO BEACH, Calif., June 12,...

The 47th Annual NYU International Hospitality Investment Forum Explored the Future of the Global Hospitality Industry and Empowered Hospitality and Financial Executives with the...

NYU IHIF 2026 Takes Place May 31-June 2 at the Marriott Marquis in New York 
NYU IHIF 2026 Takes Place May 31-June 2 at the Marriott Marquis in New York

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTechnologies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers